Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | PDC*lung01 + Pemetrexed Disodium |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
PDC*lung01 | PDClung01|Therapeutic Cancer Vaccine PDC*lung01 | PDC*lung01 is a cancer vaccine comprising plasmacytoid dendritic cells armed with seven lung tumor antigen-derived peptides, which may result in priming and expansion of CD8-positive T cells, potentially inducing an anti-tumor immune response (Annals of Oncology 33 (2022): S1086). | ||
Pemetrexed Disodium | Alimta | LY231514|Ciambra|pemetrexed | Chemotherapy - Antimetabolite 14 | Alimta (pemetrexed disodium) is an antifolate that inhibits thymidylate synthase (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03970746 | Phase Ib/II | PDC*lung01 + Pembrolizumab PDC*lung01 + Pemetrexed Disodium PDC*lung01 | Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC | Active, not recruiting | POL | NLD | FRA | DEU | BEL | 0 |